To corroborate our pathway hypothesis, in 4T1 orthotopic breast cancer mice model, VEGFR2-TKI was treated alone or in combination with multiple immunotherapy, including an anti-IL17A mAb, anti-PD-1 mAb and anti-Ly6G mAb. Here, IL17A is linked to breast carcinoma.